Top

Published in:

Open Access 01-06-2011

The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry

Authors: Juliana C. N. Chan, Wingyee So, Ronald C. W. Ma, Peter C. Y. Tong, Rebecca Wong, Xilin Yang

Published in: Current Cardiovascular Risk Reports | Issue 3/2011

Abstract

Diabetes is a complex disease characterized by chronic hyperglycemia and multiple phenotypes. In 1995, we used a doctor-nurse-clerk team and structured protocol to establish the Hong Kong Diabetes Registry in a quality improvement program. By 2009, we had accrued 2616 clinical events in 9588 Chinese type 2 diabetic patients with a follow-up duration of 6 years. The detailed phenotypes at enrollment and follow-up medications have allowed us to develop a series of risk equations to predict multiple endpoints with high sensitivity and specificity. In this prospective database, we were able to validate findings from clinical trials in real practice, confirm close links between cardiovascular and renal disease, and demonstrate the emerging importance of cancer as a leading cause of death. In addition to serving as a tool for risk stratification and quality assurance, ongoing data analysis of the registry also reveals secular changes in disease patterns and identifies unmet needs.

Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.PubMedCrossRef

Alleyne G, Stuckler D, Alwan A. The hope and the promise of the UN Resolution on non-communicable diseases. Global Health. 6:15 doi:10.1186/1744-8603-6-15.

• Chan JCN, Gagliardino JJ, Baik SH, Chantelot JM, Ferreirae SRG, Hancuf N, et al. Multi-faceted determinants for achieving glycaemic control: The International Diabetes Management Practice Study (IDMPS). Diabetes Care. 2009;32:227–33. This article reports the rates of adherence to recommended care processes and treatment targets in over 10,000 diabetic patients outside America and Europe and provides insights regarding predictors related to patients, care providers and care systems for attaining HbA1c goals. PubMedCrossRef

Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M, et al. Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabet Med. 1993;10:371–7.PubMedCrossRef

Yang X, So WY, Tong PC, Ma RC, Kong AP, Lam CW, et al. Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med. 2008;168:451–7.PubMedCrossRef

So WY, Yang X, Ma RC, Kong AP, Lam CW, Ho CS, et al. Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Metab Res Rev. 2008;24:238–46.PubMedCrossRef

Parving HH, Gall MA, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int. 1992;41:758–62.PubMedCrossRef

Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2005;48:1674–5.CrossRef

So WY, Chan N, Tong PCY, Chow CC, Chan WB, Ng MCY, et al. Effect of RAAS inhibition on survival and renal outcomes in 3737 Chinese Type 2 diabetic patients. Hypertension. 2004;44:294–9.PubMedCrossRef

10.

Luk A, Chan JC. Diabetic nephropathy–what are the unmet needs? Diabetes Res Clin Pract. 2008;82 Suppl 1:S15–20.PubMedCrossRef

11.

So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care. 2006;29:2046–52.PubMedCrossRef

12.

Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–8.PubMedCrossRef

13.

Cheng AY, Kong AP, Wong VW, So WY, Chan HL, Ho CS, et al. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. Diabetologia. 2006;49:1777–84.PubMedCrossRef

14.

Wong CK, Ho AW, Tong PC, Yeung CY, Chan JC, Kong AP, et al. Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy. J Clin Immunol. 2008;28:36–43.PubMedCrossRef

15.

Wong CK, Ho AW, Tong PC, Yeung CY, Kong AP, Lun SW, et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol. 2007;149:123–31.PubMedCrossRef

16.

Leung WYS, So WY, Tong PCY, Chan NN, Chan JCN. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005;118:1414.e1421–7.CrossRef

17.

• Chan JCN, So WY, Yeung CY, Ko GTC, Lau IT, Tsang MW, et al. The SURE Study: Effects of Structured versus Usual care on Renal Endpoint in Type 2 diabetes: A randomized multi-centre translational study. Diabetes Care. 2009;32:977–82. This is a multicenter study that confirms the increased likelihood of attaining multiple treatment goals in type 2 diabetic patients managed by a doctor–nurse team compared to usual care and the marked reduction in incidence of end-stage renal disease and related death in those who attained three more treatment targets compared to those who did not. PubMedCrossRef

18.

Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMedCrossRef

19.

Tu ST, Chang SJ, Chen JF, Tien KJ, Hsiao JY, Chen HC, et al. Prevention of diabetic nephropathy by tight target control in an asian population with type 2 diabetes mellitus: a 4-year prospective analysis. Arch Intern Med. 2010;170:155–61.PubMedCrossRef

20.

Morrish NJ, Wang S, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational survey of vascular diseases in diabetes. Diabetologia. 2001;44:S14–21.PubMedCrossRef

21.

Woodward M, Zhang X, Barzi F, Pan W, Ueshima H, Rodgers A, et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care. 2003;26:360–6.PubMedCrossRef

22.

Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med. 7:e1000236. 2010.

23.

Chan JCN, Cheung CK, Cheung MYF, Swaminathan R, Critchley JAJH, Cockram CS. Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care. 1995;18:1013–4.PubMedCrossRef

24.

Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I et al: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med, 364:829–841, 2011.

25.

Yang X, So WY, Ma RC, Ko GT, Kong AP, Wang Q, et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer. 2008;15:597–607.PubMedCrossRef

26.

Yang X, Ma RC, Yee So W, Yu LW, Kong AP, Ko GT, et al. Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry. Cancer. 2010;117:862–871.

27.

Yang X, Ma RC, So WY, Ko GT, Kong AP, Zhao H, et al. White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes. Diabetes Res Clin Pract. 2009. 87:117–125.

28.

Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT, et al. Additive interaction between the Renin-Angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes. 2009;58:1518–25.PubMedCrossRef

29.

Hernandez-Diaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia. 2010;53:802–8.PubMedCrossRef

30.

Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.PubMedCrossRef

31.

Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.PubMedCrossRef

32.

Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes. 2010;59:1254–60.PubMedCrossRef

33.

Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2010;54:25–31.PubMedCrossRef

34.

Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef

35.

• Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129–40. This is a comprehensive review article summarizing what we know about the Asian diabetic population in terms of epidemiology, risk factors, and pathophysiology. It also highlights the importance of diabetic kidney disease, gestational diabetes, and childhood obesity in setting up a vicious cycle of diabetes begetting diabetes as well as the emerging importance of cancer as a cause of death in Asian type 2 diabetic patients. PubMedCrossRef

36.

Kong AP, Yang X, Ko GT, So WY, Chan WB, Ma RC, et al. Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. Diabetes Care. 2007;30:953–9.PubMedCrossRef

37.

Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.PubMedCrossRef

38.

Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Anderesen S, Arner P. For the irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group: the effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.PubMedCrossRef

39.

Luk AO, Yang X, Ma RC, Ng VW, Yu LW, Lau WW, et al. Association of statin use and development of renal dysfunction in type 2 diabetes—the Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010;88:227–33.PubMedCrossRef

40.

Yang XL, So WY, Ma RCW, Ko GTC, Kong APS, Lam CWK, et al. Effects of albuminuria and renal dysfunction on development of dyslipidaemia in Type 2 diabetes—Hong Kong Diabetes Registry. Nephrology, Dialysis, Transplantation. 2008;23:2834–2840.

41.

Ting RZ, Yang X, Yu LW, Luk AO, Kong AP, Tong PC, et al. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol. 2010;9:77.

42.

Leung WY, So WY, Stewart D, Lui A, Tong PC, Ko GT, et al. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients–a longitudinal observational study. Cardiovasc Diabetol. 2009;8:57.PubMedCrossRef

43.

Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.PubMedCrossRef

44.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41.PubMedCrossRef

45.

Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010;87:211–8.PubMedCrossRef

46.

So WY, Wang Y, Ng MC, Yang X, Ma RC, Lam V, et al. Aldose reductase genotypes and cardio-renal complications—a 8-year prospective analysis of 1074 Type 2 diabetic patients. Diabetes Care. 2008;31:2148–53.PubMedCrossRef

47.

Wang Y, Ng MC, So WY, Tong PC, Ma RC, Chow CC, et al. Prognostic effect of insertion/deletion polymorphism of the ACE gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care. 2005;28:348–54.PubMedCrossRef

48.

Baum L, Ng MC, So WY, Lam VK, Wang Y, Poon E, et al. Effect of hepatic lipase -514C→T polymorphism and its interactions with apolipoprotein C3–482C→T and apolipoprotein E exon 4 polymorphisms on the risk of nephropathy in Chinese type 2 diabetic patients. Diabetes Care. 2005;28:1704–9.PubMedCrossRef

49.

Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA. 2010;304:881–9.PubMedCrossRef

50.

Song XY, Lee SY, Ma RC, So WY, Cai JH, Tam C, et al. Phenotype-genotype interactions on renal function in type 2 diabetes: an analysis using structural equation modelling. Diabetologia. 2009;52:1543–53.PubMedCrossRef

51.

Wang Y, Luk AO, Ma RC, So WY, Tam CH, Ng MC, et al. Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes–an 8-year prospective cohort analysis of 1297 patients. Diabet Med. 2010;27:376–83.PubMedCrossRef

52.

Luk AO, Wang Y, Ma RC, Tam CH, Ng MC, Lam V, et al. Predictive role of polymorphisms in interleukin-5 receptor alpha-subunit, lipoprotein lipase, integrin A2 and nitric oxide synthase genes on ischemic stroke in type 2 diabetes-An 8-year prospective cohort analysis of 1327 Chinese patients. Atherosclerosis. 2011;215:130–135.PubMed

53.

Chan JCN, Lau MSW, Wong YM, Chow CC, Yeung VTF, Loo KM, et al. Delivery of diabetes care—the experience at the Prince of Wales Hospital. In Hospital Authority Quality Bulletin. 1997:3–21

54.

• Chan JCN, So WY, Ko G, Tong PCT, Yang XL, Ma RCW, et al. The Joint Asia Diabetes Evaluation (JADE) program: a web-based program to translate evidence to clinical practice in type 2 diabetes. Diabet Med 2009;26:693–9. This is a translational program that validates the use of various risk equations to predict multiple endpoints in Asian populations and discusses the challenges and opportunities in implementing chronic care. PubMedCrossRef

55.

• Ko GT, So WY, Tong PC, Le Coguiec F, Kerr D, Lyubomirsky G, et al. From design to implementation—the Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program. BMC Med Inform Decis Mak. 2010;10:26. This is a translational program that uses state of the art information technology to combine the concept of risk stratification and protocol-driven care to enable doctors to establish a diabetes registry for quality assurance and use of a multidisciplinary team to implement structured care. PubMedCrossRef

56.

Yang X, So WY, Kong AP, Ma RC, Ko GT, Ho CS, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol. 2008;101:596–601.PubMedCrossRef

57.

Ma RC, So WY, Yang X, Yu LW, Kong AP, Ko GT, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol. 2008;51:2045–50.PubMedCrossRef

58.

Tong PCY, Kong APS, So WY, Ng MHL, Yang XL, Ozaki R, et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes mellitus. Diabetes Care. 2006;29:2439–44.PubMedCrossRef

59.

Tong PC, Kong AP, So WY, Yang X, Ng MC, Ho CS, et al. Interactive effect of retinopathy and macroalbuminuria on all-cause mortality, cardiovascular and renal end points in Chinese patients with Type 2 diabetes mellitus. Diabet Med. 2007;24:741–6.PubMedCrossRef

60.

Tong PCY, Lee KF, So WY, Ng MCY, Chan WB, Lo MKW, et al. Association of white blood cell counts with macrovascular and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care. 2004;27:216–22.PubMedCrossRef

61.

Lo MKW, Lee KF, Chan N, Leung W, Ko G, Chan WB, et al. Effects of gender, Helicobacter pylori (HP) and hepatitis B virus serology status on cardiovascular and renal complications in Chinese Type 2 diabetic patients with overt nephropathy. Diab Obes Metab. 2004;6:223–30.CrossRef

62.

Yang X, Ma RC, So WY, Kong AP, Ko GT, Ho CS, et al. Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 diabetes mellitus. Cardiovasc Diabetol. 2008;7:9.PubMedCrossRef

63.

Yang X, So WY, Kong AP, Ho CS, Lam CW, Stevens RJ, et al. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care. 2007;30:65–70.PubMedCrossRef

64.

Yang X, So WY, Ma RC, Ko GT, Kong AP, Ho CS, et al. Thresholds of risk factors for ischemic stroke in type 2 diabetic patients with and without albuminuria-A non-linear approach. Clin Neurol Neurosurg. 2008;110:701–709

65.

Yang X, Kong AP, So WY, Ma RC, Ho CS, Lam CW, et al. Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes. Diabetes Metab Res Rev. 2007;23:220–6.PubMedCrossRef

66.

Yang X, Ko GT, So WY, Ma RC, Kong AP, Lam CW, et al. Additive interaction of hyperglycaemia and albuminuria on risk of ischemic stroke in type 2 diabetes mellitus—Hong Kong Diabetes Registry. Diabetes Care. 2008;31:2294–2300.

67.

Luk AO, So WY, Ma RC, Kong AP, Ozaki R, Ng VS, et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with Type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care. 2008;31:2357–61.PubMedCrossRef

68.

Yang XL, So WY, Kong AP, Clarke P, Ho CS, Lam CW, et al. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia. 2006;49:2299–308.PubMedCrossRef

69.

Yang XL, So WY, Kong AP, Ho CS, Lam CW, Ng MH, et al. Modified end-stage renal disease risk score for Chinese type 2 diabetic patients-the Hong Kong Diabetes Registry. Diabetologia. 2007;50:1348–50.PubMedCrossRef

70.

Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP, et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010;90:343–51.PubMedCrossRef

71.

Yang X, So WY, Ma RC, Kong AP, Lee HM, Yu LW, et al. Low HDL Cholesterol, Metformin Use and Cancer Risk in Type 2 Diabetes—the Hong Kong Diabetes Registry. Diabetes Care. 2011;34:375–380.

Title: The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry
Authors: Juliana C. N. Chan
Wingyee So
Ronald C. W. Ma
Peter C. Y. Tong
Rebecca Wong
Xilin Yang
Publication date: 01-06-2011
Publisher: Current Science Inc.
Published in: Current Cardiovascular Risk Reports / Issue 3/2011
Print ISSN: 1932-9520
Electronic ISSN: 1932-9563
DOI: https://doi.org/10.1007/s12170-011-0172-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Complexity of Vascular and Non-Vascular Complications of Diabetes: The Hong Kong Diabetes Registry

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Case Series of Takotsubo Cardiomyopathy

Jackson Heart Study: A Perspective at Ten Years

Valvular Heart Disease in Aging Women

Cardiovascular Disease in Asian Indians Living in the United States

The Combined Burden of Diabetes and Cardiovascular Disease in Indigenous Australians

Inflammation in Relation to Cardiovascular Disease Risk: Comparison of Black and White Women in the United States, United Kingdom, and South Africa

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page